Medlab Clinical Ltd. announced that it has executed a commercial agreement with TASALK. Over the past several months both technical and business teams at MDC and TASALK have worked together to transfer NanaBisTM (Medlab's patented cannabis-based medicine) production and analytical services to TASALK, allowing for significant ramped up manufacturing, increases in overall product quality and a stronger manufacturing compliance for TGA, FDA and EMA. NanaBisTM is currently supplied under the Australian Government's Special Access Scheme and the subject of various global opportunities. In addition, NanaBisTM is also part of the recently announced, TGA approved Observational Study, where Medlab is looking to recruit 2,000 patients in the Study. This agreement helps to facilitate the anticipated growth in demand. NanaBis is undergoing drug development so as to meet the approval requirements of the TGA, FDA and EMA. TASALK, a global leader in the extraction and purification of high value high-value plant-derived products for the pharmaceutical industry have added Medicinal Cannabis products and services to their portfolio including; cultivation, manufacturing, formulation, analytical and release for supply. TASALK has been granted all the necessary ODC and TGA licences required for these activities.